✦ LIBER ✦

Association between the level of circulating bioactive tumor necrosis factor α and the tumor necrosis factor α gene polymorphism at −308 in patients with rheumatoid arthritis treated with a tumor necrosis factor α inhibitor

✍ Scribed by Hubert Marotte; Béatrice Arnaud; Jennifer Diasparra; Saloua Zrioual; Pierre Miossec

Publisher: John Wiley and Sons
Year: 2008
Tongue: English
Weight: 143 KB
Volume: 58
Category: Article
ISSN: 0004-3591
DOI: 10.1002/art.23430

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Tumor necrosis factor α haplotypes versu

Tumor necrosis factor α haplotypes versus tumor necrosis factor α −308 G/A polymorphism in the prediction of infliximab treatment efficacy in rheumatoid arthritis

✍ Bénédicte Mugnier; Jean Roudier 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 112 KB

Tumor necrosis factor α 5′-flanking regi

Tumor necrosis factor α 5′-flanking region, tumor necrosis factor receptor II, and HLA–DRB1 polymorphisms in Japanese patients with rheumatoid arthritis

✍ Tsukasa Shibue; Naoyuki Tsuchiya; Tae Komata; Masaki Matsushita; Michiko Shiota; 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 67 KB

Polymorphism at position −308 of the tum

Polymorphism at position −308 of the tumor necrosis factor α gene influences outcome of infliximab therapy in rheumatoid arthritis

✍ Benedicte Mugnier; Nathalie Balandraud; Albert Darque; Chantal Roudier; Jean Rou 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 62 KB

## Abstract ## Objective To test whether the G‐to‐A polymorphism at position −308 in the promoter of the tumor necrosis factor α (TNFα) gene influences response to infliximab therapy in patients with rheumatoid arthritis (RA). ## Methods We genotyped 59 RA patients by polymerase chain reaction a

Influence of −308 A/G polymorphism in th

Influence of −308 A/G polymorphism in the tumor necrosis factor α gene on etanercept treatment in rheumatoid arthritis

✍ Guis, Sandrine ;Balandraud, Nathalie ;Bouvenot, Julien ;Auger, Isabelle ;Toussir 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 76 KB

Individualized monitoring of drug bioava

Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor α inhibitor infliximab

✍ Klaus Bendtzen; Pierre Geborek; Morten Svenson; Lotta Larsson; Meliha C. Kapetan 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 151 KB 👁 1 views

## Abstract ## Objective Infliximab, an anti–tumor necrosis factor α (anti‐TNFα) antibody, is effective in the treatment of several immunoinflammatory diseases. However, many patients experience primary or secondary response failure, suggesting that individualization of treatment regimens may be b

Relationship between α1-antitrypsin inac

Relationship between α1-antitrypsin inactivation and tumor necrosis factor α concentration in the synovial fluid of patients with rheumatoid arthritis

✍ Keith Chidwick; Catherine E. Whichelow; Zhi Zhang; Kevin Fairburn; John A. Sachs 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 English ⚖ 429 KB

Objective. To examine the relationship between qantitrypsin (a,AT) specific activity and tumor necrosis factor a (TNFa) concentration in synovial fluid from 48 patients with rheumatoid arthritis. Methods.The specific activity of alAT was calculated from the measurement of a,AT concentration (by roc